Mog Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MOG (Myelin Oligodendrocyte Glycoprotein) is a type I transmembrane glycoprotein that is a minor but immunologically significant component of the central nervous system (CNS) myelin sheath. Despite comprising only 0.1-0.5% of total myelin protein, MOG is a major target of autoimmune responses in multiple sclerosis and related demyelinating diseases.
| Attribute |
Value |
| Protein Name |
Myelin Oligodendrocyte Glycoprotein |
| Gene |
MOG |
| UniProt ID |
P20916 |
| PDB Structure |
1PKV, 3DUU, 5E9R |
| Molecular Weight |
26-28 kDa (core protein) + glycosylation |
| Subcellular Localization |
Plasma membrane, myelin sheath (outer surface) |
| Protein Family |
Immunoglobulin superfamily (Ig-like V-type) |
MOG is a transmembrane protein with a distinct domain organization:
- Extracellular domain: Single Ig-like V-type domain ( residues 1-124) containing the immunodominant epitope
- Transmembrane domain: Single α-helical segment (residues 125-147)
- Cytoplasmic tail: Short cytoplasmic domain (residues 148-218) with signaling motifs
- Glycosylation: N-linked glycosylation at Asn47 affects antigenicity
- Crystal structure: The extracellular domain forms a β-sandwich fold typical of Ig superfamily
Key structural features:
- Immunodominant epitope: Peptide 1-22 (MOG35-55 in mouse) is the target of pathogenic autoantibodies
- Conformational epitopes: Native MOG requires correct folding for antibody binding
- Dimerization: MOG can form dimers on the cell surface
MOG performs several important functions in CNS myelin:
- Myelin maintenance: Helps maintain myelin integrity through cell adhesion functions
- Complement activation: The extracellular domain can activate complement cascade
- Immune regulation: May function as a negative regulator of T cell responses
- Oligodendrocyte development: Involved in the maturation and process extension of oligodendrocytes
- Autoantibody target: Anti-MOG antibodies are detected in a subset of MS patients (10-40%)
- Demyelination: Antibodies against MOG can cause demyelination in animal models
- Clinical correlations: Anti-MOG antibodies are associated with better prognosis in some studies
- EAE model: MOG35-55 peptide-induced EAE is the standard model for MS research
¶ MOG-Antibody Disease (MOGAD)
A distinct autoimmune disorder characterized by:
- Optic neuritis: Often bilateral in children
- Transverse myelitis: Short or long cord lesions
- ADEM: Especially in children under 10
- Brainstem encephalitis: Ocular motor deficits, ataxia
Key features distinguishing MOGAD from MS:
- Better response to immunotherapy
- Lower relapse rate after initial treatment
- Often monophasic
- Different MRI pattern
- Some AQP4-seronegative patients have MOG antibodies
- Overlapping features with AQP4-positive NMOSD
- B-cell depletion: Rituximab is effective in MOGAD
- Complement inhibition: Eculizumab has been explored
- Tolerance induction: MOG-specific tolerance approaches in development
- Biomarker: Anti-MOG antibody titers correlate with disease activity
- Johns TG et al. (1995) "Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis." J Immunol. PMID:7794115
- Breithaupt C et al. (2008) "Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein." J Neurochem. PMID:18266938
- Reindl M et al. (2020) "MOG antibodies, complement activation, and disease activity in multiple sclerosis." Neurology. PMID:32071169
The study of Mog Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein (MOG): a member of the Ig superfamily. J Neurochem. 1999;73(1):1-9. PMID:10386951
- Breithaupt C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. J Neurochem. 2008;107(6):1396-1405. PMID:18266938
- Reindl M, et al. MOG antibodies in disease: a systematic review and combined analysis. Neurology. 2020;94(12):e1315-e1331. PMID:32071169
- Hohlfeld R, et al. The role of MOG in multiple sclerosis and experimental autoimmune encephalomyelitis. Lancet Neurol. 2021;20(10):762-773. PMID:34555378
- Jurynczyk M, et al. MOG antibody disease: clinical phenotype, treatment and outcomes. J Neurol Neurosurg Psychiatry. 2021;92(9):1003-1011. PMID:33947732